Phase II Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Diseases and Conditions Researched
What is the purpose of this trial?
-To assess the incidence of grade 3 or higher drug related adverse event in the study population during the induction period of ipilimumab (Day 1 of treatment to Week 24).
-To assess the best overall response rate (BORR) in the study population by mWHO, immune-related response criteria (irRC), and CA125 Rustin Criteria. [Rustin, GJ 1996; Gordon, JS 2003]
Click here for detailed participation information for this trial.
|Sponsor:||Bristol-Myers Squibb Company|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.